Neonatal and Young Infant HSV Infection Questionnaire	APSU Office Use Only	
Australian Paediatric Surveillance Unit	Study ID #:	
If you have any questions about this form please contact the APSU (02) 9845 3005; SCHN-APSU@health.nsw.gov.au	Month/Year Report:	
<u>Instructions</u> : Please answer each question by ticking the appropriate box or writing your response in the space provided. DK=Don't Know; NA = Not Applicable;	Version 1.0: Date 11/2	11/2016

REPORTING CLINICIAN'S DETAILS			
1. APSU Dr Code/Name:	/		
2. Date questionnaire completed:	//		
PATIENT DETAILS			
3. First 2 letters of first name:	——		
4. First 2 letters of surname:			
5. Date of Birth:	//_		
6. Sex:	☐ Male	☐ Female	
7. Postcode of family:			
8. Racial Background (select all that apply):	\square Aboriginal	\square Caucasian	☐ Pacific Islander
	☐ Torres Strait Isl	ander	☐ African
	☐ Asian	\square DK	☐ Other (specify):
9. Country of birth of the child:	☐ Australia	☐ Other (specij	fy):
10. Did you make the diagnosis of primary HSV			
infection?	☐ Yes (<i>please go</i>	to Q11)	□ No
If this patient is primarily cared for by another physicia and return this form to the APSU. If no other re	=	=	•
Physician's Name:	Clinic/hospital:		
11. Date patient first seen by you:	//_		
MATERNAL			
12. Mother's age in years:			
13. Mother's country of birth:	Australia	Other (specify):_	
14. Number of previous pregnancies:			
15. Number of previous deliveries:			
BIRTH DETAILS			
16. Birth weight (grams):			
17. Gestational age at birth:	completed	l weeks	
18. Multiple Birth?	Yes	No If yes	, specify birth order (e.g. Twin 2)
19. Delivery:	Vaginal - no ins	struments 🔲 In	nstrumental vaginal Caesarean
20. Time between membrane rupture and delivery:	hours	Пр	K
21. Was a scalp monitor applied?	Yes] _{No} □ _D	К
22. Age baby first saw a doctor with manifestations of			_
possible HSV infection ?	□□ months o	r LLL	☐ days
CLINICAL MANIFESTATIONS IN THE INFANT			
23. Please indicate where (in which system) clinical signs	were noted and ag		
		1 <u> </u>	of onset (months or days)
(a) Skin, or Mouth	∐ Yes	JNo LL	☐ months ☐ ☐ days
(a) Eyes	∐ _{Yes} ∟	J _{No} ∐L	months days

(bi) Seizures,		☐ Yes	∐ No	☐☐ months	☐ ☐ days
(bii) Irritability		Yes	No	□□ months	days
(biii) Lethargy		Yes	No	□□ months	days
(biv) Apnoea		Yes	\square No	□□ months	days
(c) Respiratory (e.g. pneumon	itis)	Yes	\square_{No}	□□ months	☐ ☐ days
(d) Hepatic (ie: elevated liver fo	unction tests, jaundice)	Yes	\square No	□□ months	☐ ☐ days
(e) Bleeding or DIC		Yes	\square No	□□ months	days
(f) Cardiac (e.g. hypotension,)	poor perfusion)	Yes	\square_{No}	□□ months	days
(g) Fever (>37°C)		Yes	\square_{No}	□□ months	days
(h) Other (specify)		Yes	\square No	□□ months	days
INVESTIGATIONS ON INFANT					·
If these specimens were sent pleas	se complete the results	(DK = Don't Kı	nowl		
24. HSV typing (on any sample)?	e complete the results	HSV 1	HSV 2	☐ Not done	□ _{DK}
25. HSV PCR positive surface swab	or respiratory?	Yes	□ No	Not done	DK Site(s)
26. HSV CSF PCR positive?	,	Yes	□No	Not done	DK Site(s)
27. HSV Blood PCR positive?		Yes	□No	☐ Not done	DK Site(s)
28. HSV Immunofluorescence posi	itive?	Yes	□No	☐ Not done	DK Site(s)
29. HSV Isolated on Viral culture?		Yes	No	☐ Not done	DK Site(s)
OTHER CSF EXAMINATION RESUL	.TS?				
30. Was a lumbar puncture perfor	med at diagnosis?	Yes	\square No	DK If Yes,	Date//
31. <i>If YES</i> , Number of CSF white ce	_			, , , , , , , , , , , , , , , , ,	
Number of CSF red cells/mm ³ :					
TREATMENT, FOLLOW UP INVEST		HVI AXIS OF TI	— — HE INIEANIT		
32. Was the baby treated for HSV		☐ Yes	∐ No	☐ DK If Yes,	please provide details:
DRUG Used	Age when started months days	Dose m	g/ kg/ per/ day	Route	Duration (days)
33. Were antiviral drugs given as n	rophylaxis to prevent				
33. Were antiviral drugs given as precurrence after treatment course		Yes	□No	DK If Yes,	please provide details:
recurrence after treatment cou	urse completed? Age when started				please provide details: Duration (days)
	urse completed?		No g/ kg/ per/ day	DK If Yes,	please provide details: Duration (days)
recurrence after treatment cou	urse completed? Age when started				
recurrence after treatment cou	Age when started months days				
recurrence after treatment cou	Age when started months days			Route	
recurrence after treatment countries of the proof of the	Age when started months days	Dose mg	g/ kg/ per/ day	Route	Duration (days)
recurrence after treatment countries of the properties of the prop	Age when started months days	Dose mg	g/ kg/ per/ day	Route	Duration (days)
recurrence after treatment countries of the countries of	Age when started months days med at the end of ells/mm ³	Dose mg	g/ kg/ per/ day	Route DK If Yes, Negative	Duration (days) Date//
recurrence after treatment countries of the proof of the	Age when started months days med at the end of ells/mm ³ IgM: (specify result)	Yes	g/ kg/ per/ day	Route DK If Yes,	Duration (days) Date//
recurrence after treatment countries of the countries of	Age when started months days med at the end of ells/mm ³ IgM: (specify result)	Yes Positive	g/ kg/ per/ day	Route DK If Yes, Negative Date/_	Duration (days) Date//
recurrence after treatment countries of the proof of the	Age when started months days med at the end of ells/mm ³ IgM: (specify result)	Yes	g/ kg/ per/ day	Route DK If Yes, Negative	Duration (days) Date//
recurrence after treatment country of the proof of the pr	Age when started months days med at the end of ells/mm ³ IgM: (specify result)	Yes Positive	g/ kg/ per/ day	Route DK If Yes, Negative Date/_	Duration (days) Date//

39. CNS Imaging result:		□ _{No}	rmal	Abnormal	
		□Not	t Done	Date of scan	$]/\square\square/\square\square$
		Please	specify result:		
40. EEG performed?		Yes		□No	
41. If Yes, EEG Results:		□ _{No}	rmal	Abnormal	
		Date of	scan 🗌 🗎 / 🔲	\square / \square \square	
		Please	specify result:		
OUTCOME AT THIS PRESENTATIO	N				
42. Infant: survived?		□ _{Yes}		□No	
43. If died, Date of death:			$/\Box\Box/\Box\Box$		
44. If survived, were there obvious	s sequelae at discharg	e: Yes	5	No	□dK
If yes, please specify:					
SOURCE OF INFECTION					
Genital Herpes		Mothe	r Father	Other maternal sex	ual partner
45. No known genital herpes at an	y time	\sqcup			
46. Genital herpes before (& durin	ng) this pregnancy				
47. Genital herpes during this preg	gnancy for first time				
48. Genital herpes diagnosed first	time after delivery				
49. Other:					
Non-Genital Herpes		Mothe	r Father	*Other (please spec	cify)
50. Past history of non genital her	pes (oral or whitlow)				
50. Past history of non genital her51. Oral herpes at or soon after de					
	elivery				
51. Oral herpes at or soon after de52. Herpetic whitlow at or soon af *other = contact other than par	elivery ter delivery rent eg; Hospital staff,	Sibling/I	Relative.		
 51. Oral herpes at or soon after de 52. Herpetic whitlow at or soon af *other = contact other than par 53. Was Maternal antiviral therapy 	elivery ter delivery rent eg; Hospital staff,				
51. Oral herpes at or soon after de52. Herpetic whitlow at or soon af *other = contact other than par	elivery ter delivery rent eg; Hospital staff,	Sibling/l			
51. Oral herpes at or soon after de52. Herpetic whitlow at or soon af *other = contact other than par53. Was Maternal antiviral therapy pregnancy?	elivery ter delivery rent eg; Hospital staff,	Yes			tion (days)
 51. Oral herpes at or soon after de 52. Herpetic whitlow at or soon af *other = contact other than par 53. Was Maternal antiviral therapy pregnancy? 54. If Yes, please provide details: 	elivery ter delivery rent eg; Hospital staff , y given during	Yes	No		tion (days)
 51. Oral herpes at or soon after de 52. Herpetic whitlow at or soon af *other = contact other than par 53. Was Maternal antiviral therapy pregnancy? 54. If Yes, please provide details: 	elivery ter delivery rent eg; Hospital staff , y given during	Yes	No		tion (days)
 51. Oral herpes at or soon after de 52. Herpetic whitlow at or soon af *other = contact other than par 53. Was Maternal antiviral therapy pregnancy? 54. If Yes, please provide details: DRUG Used MATERNAL INVESTIGATIONS:	elivery ter delivery rent eg; Hospital staff, y given during Dose mg/ kg/ per	Yes	No		tion (days)
 51. Oral herpes at or soon after de 52. Herpetic whitlow at or soon af *other = contact other than par 53. Was Maternal antiviral therapy pregnancy? 54. If Yes, please provide details: DRUG Used 	elivery ter delivery rent eg; Hospital staff, y given during Dose mg/ kg/ per	Yes	No Route		tion (days)
 51. Oral herpes at or soon after de 52. Herpetic whitlow at or soon af *other = contact other than par 53. Was Maternal antiviral therapy pregnancy? 54. If Yes, please provide details: DRUG Used MATERNAL INVESTIGATIONS: 55. Was the mother's HSV type sytested? 	elivery ter delivery rent eg; Hospital staff, y given during Dose mg/ kg/ per	/ day	No Route	Dura	tion (days)
 51. Oral herpes at or soon after de 52. Herpetic whitlow at or soon af *other = contact other than par 53. Was Maternal antiviral therapy pregnancy? 54. If Yes, please provide details: DRUG Used MATERNAL INVESTIGATIONS: 55. Was the mother's HSV type specified? If Yes 	elivery ter delivery rent eg; Hospital staff, y given during Dose mg/ kg/ per	/ day S Yes	Route No	Durat	e Date//
 51. Oral herpes at or soon after design of the state of the s	elivery ter delivery rent eg; Hospital staff, y given during Dose mg/ kg/ per	Yes / day S Pos Pos	Route No No No Sitive Negati	ve Indeterminate	

Thank you for your assistance with this research project

Please return this questionnaire to the APSU via email to <u>SCHN-APSU@health.nsw.gov.au</u> or via Fax: (02) 9845 3082 or by mail to: Australian Paediatric Surveillance Unit, Kids Research, Locked Bag 4001, Westmead NSW 2145

The APSU is affiliated with the Royal Australasian College of Physicians (Paediatrics and Child Health Division) and Faculty of Medicine and Health, The University of Sydney.

The APSU is funded by the Australian Government Department of Health.

This study has been approved by a Human Research Ethics Committee properly constituted under NHMRC guidelines